Lilly reports strong earnings, after year-ago loss
34149
Eli Lilly and Co.  on Friday  reported strong second-quarter earnings, fueled by strong  revenue growth of newer drugs, including an almost doubling of  sales for its Cymbalta depression treatment.
350697
update Earnings per share rise compared with a year ago, but company misses analysts' expectations by a long shot.
649682
The company turned in a wider Q1 loss but is still on track for a profitable year.
387898
Pfizer Inc, Novartis AG and Wyeth all  saw quarterly earnings hit by charges on Thursday, while Eli  Lilly and Co exceeded Wall Street expectations as third-quarter  sales of several of its drugs outpaced analysts' estimates.
312721
The biotechnology company reported fourth-quarter net income of $201.2 million on strong sales of its two leading drugs, Rituxan and Avonex.
326217
Bayer unveiled a mixed set of second-quarter results, with operating profit beating analysts' expectations although bottom-line earnings stagnated and the pharmaceuticals division continued to cause headaches for the German maker of Aspirin.
393883
Schering continues its strong sales and earnings growth.
346082
Eli Lilly and Co  on Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.
429262
Eli Lilly and Co.  said on Wednesday its fourth-quarter earnings fell, hurt by a number of special charges.
741054
Eli Lilly and Co. LLY.N on Thursday  said its third-quarter earnings rose as growing demand for its  medicines offset higher spending to market recently approved  treatments.
692786
NEW YORK - Pfizer Inc. said Wednesday that third quarter earnings, excluding charges, beat Wall Street expectations by a penny, on strong sales of Lipitor and Celebrex medicines.
468404
Eli Lilly and Co. LLY.N on Thursday  said it expects 2005 earnings to rise as higher sales of its  newer drugs offset a decline in its top-selling schizophrenia  drug Zyprexa.
740875
Lucent Technologies yesterday posted higher fiscal fourth- quarter earnings, helping lift the telecommunications equipment maker to its first profitable year since 2000.
41158
Eli Lilly and Co.  said on Wednesday its fourth-quarter earnings fell sharply, hurt by a $495 million charge to cover a settlement with former users of its Zyprexa schizophrenia drug.
245874
Eli Lilly and Co.  said on Thursday it is on track to meet its 2006 growth forecast of 8 percent to 12 percent, but projected slower profit growth in 2007 though its revenues will grow at a faster pace next year.
634066
The company's fourth-quarter earnings beat analyst expectations.
280767
Quarterly profit beat expectations on strong growth in its international, ground and freight segments.